Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06613841 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma

Name: Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma — clinical trial record (NCT06613841)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: GBM

StatusRecruiting

PhaseEarly Phase 1

SponsorAbramson Cancer Center at Penn Medicine

Started2025-05-01

View on ClinicalTrials.gov ↗

* To perform metabolic phenotyping of treatment naïve and recurrent GBM by multitracer \[18F\]Fluciclovine and 18F-FDG PET. * To compare uptake measures of 18F-Fluciclovine and 18F-FDG and MRI quantification of glutamate and lactate levels to tumor tissue laboratory assays (RNA seq and proteomics) of glutamine/glutamate, glucose, and lactate metabolism. * To perform metabolic phenotyping of treatment naïve and recurrent GBM by advanced MRI methods at 7 Tesla

Amendment history 2 changes detected by DataLookout

2026-09-10

Primary completion pushed: 2026-10-01 → 2027-10-01

2026-09-10

Completion pushed: 2026-12-31 → 2027-12-31

Trial Details

NCT Number	NCT06613841
Lead Sponsor	Abramson Cancer Center at Penn Medicine
Conditions	Glioblastoma, Recurrent Glioblastoma, Glioblastoma Multiforme of Brain
Enrollment	15 participants
Start Date	2025-05-01
Primary Completion	2027-10-01 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-09-09